Indaptus Therapeutics is trading at $1.82 (+5.20%) as the stock stages a volatile rebound following a steep two-day selloff.
- The move appears to be a technical recovery from recent weakness rather than a response to any new company-specific catalysts or announcements.
- No material news surfaced on July 29, 2026, while the broader biotech sector and global markets remain under pressure in a risk-off environment.